110 related articles for article (PubMed ID: 21028825)
1. Preparation and evaluation of carborane analogues of tamoxifen.
Beer ML; Lemon J; Valliant JF
J Med Chem; 2010 Nov; 53(22):8012-20. PubMed ID: 21028825
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
3. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
Werner HM; Franke HR; Vermes I
Climacteric; 2005 Sep; 8(3):294-9. PubMed ID: 16390761
[TBL] [Abstract][Full Text] [Related]
5. m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators.
Ogawa T; Ohta K; Yoshimi T; Yamazaki H; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem Lett; 2006 Aug; 16(15):3943-6. PubMed ID: 16735120
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
7. Simple and efficient production of (Z)-4-hydroxytamoxifen, a potent estrogen receptor modulator.
Yu DD; Forman BM
J Org Chem; 2003 Nov; 68(24):9489-91. PubMed ID: 14629178
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel tamoxifen analogues.
Christodoulou MS; Fokialakis N; Passarella D; García-Argáez AN; Gia OM; Pongratz I; Dalla Via L; Haroutounian SA
Bioorg Med Chem; 2013 Jul; 21(14):4120-31. PubMed ID: 23735829
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
10. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
11. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of p-carborane bisphenols and their derivatives: structure-activity relationship for estrogenic activity.
Ogawa T; Ohta K; Iijima T; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2009 Feb; 17(3):1109-17. PubMed ID: 19141368
[TBL] [Abstract][Full Text] [Related]
13. Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells.
Nomura H; Kawashima H; Masaki S; Hosono TY; Matsumura K; Tamada S; Tanaka T; Nakatani T
Prostate Cancer Prostatic Dis; 2009; 12(4):375-81. PubMed ID: 19468285
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel m-carborane-containing estrogen receptor partial agonists as SERM candidates.
Ohta K; Ogawa T; Kaise A; Endo Y
Bioorg Med Chem Lett; 2015 Aug; 25(16):3213-6. PubMed ID: 26077489
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of boroxifen, a nido-carborane analogue of tamoxifen.
Valliant JF; Schaffer P; Stephenson KA; Britten JF
J Org Chem; 2002 Jan; 67(2):383-7. PubMed ID: 11798307
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
Yu Y; Zhou Q; Hang Y; Bu X; Jia W
Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
[TBL] [Abstract][Full Text] [Related]
18. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
19. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
20. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
